• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Decapeptyl 0.1
    / Ferring Pharmaceuticals


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Syringe (solution for injection)

    7 X 1 ml

    partial basket chart 13756 4513

    Dosage

    Initially, Decapeptyl 0.5 mg is administered once a day for 7 days. From the 8th day on, Decapeptyl 0.1 mg is administered once a day. Alternatively, Decapeptyl Depot (3.75 mg triptorelin as a controlled-release preparation for IM application once every 28 days) is available.


    Indications

    Precocious puberty, prostatic cancer, endometriosis, uterus myomatoses, IVF.


    Contra-Indications

    Non hormone dependent carcinoma. As this preparation suppresses the hypothalamic, pituitary and sex steroid hormones, it should not be used in pregnancy, or nursing, or in any situation where endogenous sex-hormone activity is essential. Prostatic cancer: Decapeptyl should not be prescribed to patients presenting with spinal cord compression or evidence of spinal cord metastases.


    Special Precautions

    Treatment with Decapeptyl over several months can lead to a decrease of bone density. After withdrawal of treatment, the bone loss is generally reversible within 6-9 months. Particular caution is therefore advised in patients with additional risk factors in view of osteoporosis.
    Assisted reproduction: To prevent hyperstimulation, careful monitoring of follicular growth and luteal phase especially in patients with polycystic ovaries should be performed.


    Side Effects

    Hot flushes, sweating, reversible loss of libido and reversible impotence.
    Men: The initial transient increase of serum testosterone has, in a few patients, been associated with a temporary aggravation of secondary symptoms of the disease. Close monitoring should be carried out during the first weeks of treatment. Patients at particular risk of developing ureteric obstruction should be carefully monitored, as should those at risk of developing spinal cord compression.
    Women: Non-pregnancy should be confirmed. During the first month of treatment, patients should use non-hormonal contraceptives. Women should not use preparations containing estrogens during therapy. Uterus and myoma size should be regularly measured.
    Less frequent: allergic reactions, headache, tiredness, gastralgia, recurrence of asthma, increased dysuria.
    For full details see prescribing information.


    Drug interactions

    No interactions with other drugs have been reported. For theoretical consideration, interference of calcium antagonists with the mechanism of action of GnRH and GnRH-analogues may be possible. However, first test results with triptorelin on long-term suppressibility of the serum testosterone with simultaneous therapy with calcium antagonists did not show any indication for such interaction.


    Pregnancy and Lactation

    As this preparation suppresses the hypothalamic, pituitary and sex steroid hormones, it should not be used in pregnancy, or nursing, or in any situation where endogenous sex-hormone activity is essential.


    Overdose

    Symptoms of intoxication: Due to the broad therapeutic scope of the active ingredient triptorelin, overdoses and intoxications are not to be expected.
    Therapy:  A specific antidote for Decapeptyl is not known.


    Manufacturer
    Ferring Pharmaceuticals Israel
    CLOSE